A Phase 1 interventional study of Fluoroglutamine [18F]F-GLN in Breast Cancer, sponsored by Abramson Cancer Center at Penn Medicine. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-22.
Sponsored by Abramson Cancer Center at Penn Medicine · Phase 1, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Breast Neoplasms by Abramson Cancer Center at Penn Medicine — 11 open to participants now, 22 under way, none of them phase 3. Breast Neoplasms · Abramson Cancer Center at Penn Medicine.
Among the 68 studies in Breast Neoplasms by Abramson Cancer Center at Penn Medicine, this one is the 26th largest by planned enrollment of the 45 interventional ones that give a count, is one of 3 that started in 2019, is one of 13 in phase 1, reaches primary completion later than 6 of the 21 other live ones, and was the 44th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →11 of the 68 studies in Breast Neoplasms by Abramson Cancer Center at Penn Medicine are open now, in 1 country. Recruiting first, the newest first:
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 18+
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 18+ · Women only
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 18+
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 18+
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 11
First in 1998; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 53 across the 45 interventional studies, 110 across the 22 observational. Of the 44 that completed or were terminated, 8 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
Abramson Cancer Center at Penn Medicine is the lead sponsor of 462 studies on the registry; 88 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 14 (42%) have results posted.
5 of the studies in Breast Neoplasms by Abramson Cancer Center at Penn Medicine that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06332131Abramson Cancer Center at Penn MedicineEffects of Immune Checkpoint Inhibitors on Coronary Microvasculature | 2026-11 |
| NCT03863457Abramson Cancer Center at Penn Medicine[18F] F-GLN by PET/CT in Breast Cancer | 2026-12 |
| NCT04841148Abramson Cancer Center at Penn MedicineAvelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer | 2027-07 |
| NCT03083288Abramson Cancer Center at Penn MedicineEvaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer | 2027-07 |
| NCT04855552Abramson Cancer Center at Penn MedicineTelehealth Weight Loss Program for Breast Cancer Survivors | 2027-07-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 68 studies in Breast Neoplasms by Abramson Cancer Center at Penn Medicine, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients with known or suspected primary or metastatic breast cancer with one lesion that is 1.0 cm in diameter or greater may be eligible for this study. Patients may participate in this study if they are at least 18 years of age. Up to 40 evaluable subjects will participate in a single imaging cohort. Patients will be stratified for analysis by breast cancer subtype with prioritization to recruit at least 10 estrogen-receptor-expressing (ER+) and 10 triple-negative breast cancers (TNBC). Participants may be treatment naïve or have received up to 3 weeks of treatment at the time of the [18F]F-Gln PET/CT scan.
This is an observational study; [18F]F-GLN PET/CT will not be used to direct treatment decisions. While patients and referring physicians will not be blinded to the [18F]F-GLN PET/CT results, treatment decisions are made by the treating physicians based upon clinical criteria.
[18F]F-GLN PET/CT imaging sessions will include an injection of [18F]F-GLN. Metabolism data will be collected. Pilot data will be collected to evaluate image quality and collect preliminary information on the uptake of [18F]F-GLN in breast cancer. Uptake measures will be compared to tumor markers of glutamine metabolism, when tissue is available. The safety of [18F]F-GLN will also be evaluated in all subjects.
Up to 40 patients will undergo approximately 60 minutes of dynamic PET scanning followed by up to 2 static skull-base to mid-thigh scans post injection of [18F] (2S,4R)4-fluoroglutamine ([18F]F-GLN). A baseline FDG-PET/CT will also be performed, either as a routine clinical staging/re-staging scan or as a research scan. If performed as a research scan, the scan may include an optional dynamic imaging session. Some subjects, who undergo systemic therapy as part of their clinical treatment, may also undergo an optional second [18F]F-GLN PET/CT to collect pilot data on the changes in [18F]F-GLN uptake in response to therapy. Subjects who undergo a second [18F]F-GLN PET/CT may have a second FDG-PET/CT, again either as a standard-of-care restaging study or as an optional research scan. The timing of the optional second PET scans will vary depending on the type of treatment the subject is receiving. If the subject moves during their scans, a low-dose CT attenuation may be repeated following the dynamic scan at the PI's discretion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pilot data will be collected to evaluate image quality and collect preliminary information on the uptake of \[18F\]F-Gln in breast cancer. Uptake measures will be compared to tumor markers of glutamine metabolism, when tissue is available. The safety of \[18F\]F-Gln will also be evaluated in all subjects.
Drug: Fluoroglutamine [18F]F-GLN
Evaluate the kinetics and biodistribution of \[18F\]F-GLN in primary and metastatic breast cancer.
Also known as: [18F](2S, 4R)4-Fluoroglutamine ([18F]F-GLN)
Kinetics and Biodistribution of [18F]F-GLN
Evaluate the biodistribution of \[18F\]F-GLN by measuring organ and whole body dosimetry.
Time frame: 3 years
Incidence of Adverse Events (Safety and Tolerability)
Evaluate the safety of \[18F\]F-GLN. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.
Time frame: 3 years
Association of Uptake with [18F]F-GLN
Assess the correlation of \[18F\]F-GLN with pathologic sub-types of breast cancer using standard pathology results, ER, PR, HER2.
Time frame: 3 years
Association with Tumor Markers and [18F]F-GLN
Correlate uptake of \[18F\]F-GLN with pathologic measurement of glutamine metabolism in tissue.
Time frame: 3 years
Metabolism of [18F]F-GLN
Measure the biometabolites in patient blood over time, following injection of \[18F\]F-GLN to determine the rate at which \[18F\]F-GLN is metabolized.
Time frame: 3 years
Change in Uptake of [18F]F-GLN After Therapy
Evaluate change in \[18F\]F-GLN uptake measures after therapy compared to pre-treatment baseline.
Time frame: 3 years
Plan to share: No
Started Apr 2019 (actual). Primary completion is estimated for Dec 2026, 92 months after the start.
Of 373 non-industry phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 77. This study's planned 92 months is above that.
Counting every sponsor, half of 763 studies reached it within 44 months; a quarter within 25 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Abramson Cancer Center at Penn Medicine →